Skip to main content
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading